RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Spriggs, MD
Repertoire Immune Medicines
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Yale Cancer Center
New Haven, Connecticut, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Carolina Biooncology Institute
Huntersville, North Carolina, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Oct 2018
- Primary completion
- 7 Sept 2022
- Completion
- 11 Oct 2022
- Last update posted
- 6 Dec 2022
- Registered enrollment
- 23
- Registry id
- NCT03815682
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.